Basiliximab versus steroids in double therapy immunosuppression in liver transplantation: A prospective randomized clinical trial

Transplantation

Volumn 86, Issue 7, 2008, Pages 925-931

  Lupo, Luigi ^a   Panzera, Piercarmine ^a   Tandoi, Francesco ^a   Carbotta, Giuseppe ^a   Giannelli, Gianluigi ^b   Santantonio, Teresa ^a   Rendina, Maria ^a   Gentile, Antonietta ^a   Memeo, Vincenzo ^a  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

Author keywords

Acute rejection; Liver transplantation; Monoclonal antibodies; Steroids free

Indexed keywords

BASILIXIMAB; CYCLOSPORIN A; HYDROCORTISONE; PREDNISOLONE; ANTIINFECTIVE AGENT; CORTICOSTEROID; CYCLOSPORIN; HYBRID PROTEIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ALPHA; MONOCLONAL ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; AGED; ARTICLE; BIOPSY TECHNIQUE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; FEMALE; GLUCOSE TOLERANCE; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; LIVER TRANSPLANTATION; MALE; OBESITY; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; ANTIBIOTIC PROPHYLAXIS; GRAFT REJECTION; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; REPRODUCIBILITY;

ADRENAL CORTEX HORMONES; ADULT; AGED; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; ANTIBODIES, MONOCLONAL; CYCLOSPORINE; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECOMBINANT FUSION PROTEINS; REPRODUCIBILITY OF RESULTS;

EID: 56049125963     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318186b8a3     Document Type: Article

References (25)

1. Fung J, Kelly D, Kadry K, et al. Immunosuppression in liver transplantation beyond calcineurin inhibitors. Liver Transplant 2005; 11: 267.
2. NashanB.The IL2 pathwayinclinical immunosuppression.Transplant Proc 2001; 33: 3072.
3. Sànchez-Fueyo A, Strom TB. Immunological tolerance and liver transplantation. J Hepatol 2004; 41: 698.
4. Perry I, Neuberger J. Immunosuppression: Towards a logical approach in liver transplantation. Clin Exp Immunol 2005; 139: 2.
5. Conti F, Morelon E, Calmus Y. Immunosuppressive therapy in liver transplantation. J Hepatol 2003; 39: 664.
6. Goddard S, Adams DH. New approaches to immunosuppression in liver transplantation. J Gastroenterol Hepatol 2002; 17: 116.
7. Hirose R, Pros and cons of using interleukin-2 receptor antibodies in liver transplant recipients. Liver Transplant 2002; 8: 143.
8. Shah MH, Bokhari MZM, Farooq A, et al. Safety and efficacy of basil-iximab for the prevention of acute rejection in kidney transplant recipients. Transplant Proc 2003; 35: 2737.
9. Petz W, Spada M, Bertani A, et al. Experience with the use of basil-iximab in liver transplantation - Use in pediatric and adult recipients in combination with cyclosporine or tacrolimus. Transplant Proc 2002; 34: 1966.
10. Arora N, McKiernan PJ, Beath SV, et al. Concomitant basiliximab with low-dose calcineurin inhibitors in children post-liver transplantation. Pediatr Transplant 2002; 6: 214.
11. Banff schema for grading liver allograft rejection:Aninternational consensus document. Hepatology 1997; 25:658.
12. Ormonde DG, de Boer WB, Kierath A, et al. Banff schema for grading liver allograft rejection: Utility in clinical practice. Liver Transpl Surg 1999; 5: 261.
13. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: A new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004; 240: 205.
14. Neuhaus P, Clavien PA, Kittur D, et al.; for the CHIC 304 International Liver Study Group. Improved treatment response with basiliximab immu-noprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial. Liver Transplant 2002; 8: 132.
15. Filipponi F, Salizzoni M, Grazi G, et al. Study of simulect-based, steroid-free immunosuppressive regimen in HCV+ de novo liver transplant patients: Preliminary results. Transplant Proc 2001; 33:3211.
16. Filipponi F, Callea F, Salizzoni M, et al. Double-blind comparison of hepatitis C histological recurrence rate in HCV+ liver transplant recipients given basiliximab+steroids or basiliximab+placebo, in addition to cyclosporine and azathioprine. Transplantation 2004; 78: 1488.
17. Calmus Y, Scheele JR, Gonzalez-Pinto I, et al. Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients. Liver Transplant 2002; 8: 123.
18. Leung Liu CL, Tat Fan S, Mau Lo G, et al. Interleukin-2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: a protocol with early elimination of steroids and reduction of tacrolimus dosage. Liver Transplant 2004; 10: 728.
19. Marino IR, Doria C, Scott VL, et al. Efficacy and safety of basiliximab with a tacrolimus-based regimen in liver transplant recipients. Trans plantation 2004; 78: 886.
20. Pegeaux GP, Calmus Y, Boillot O, et al.; and the French CHI Study Group. Steroid withdrawal at day 14 after liver transplantation: A double-blind, placebo-controlled study. Liver Transplantation 2004; 10: 1454.
21. Llado L, Xiol X, Figueras J, et al.; Thosin Study Group. Immunosuppression without steroids in liver transplantation is safe and reduces infection and metabolic complications: Results from a prospective multicenter randomized study. J Hepatol 2006; 44: 710. Epub 2006 Jan 24. Erratum in J Hepatol 2006; 45: 166.
22. Spada M, Petz W, Bertani A, et al. Randomized trial of basiliximab induction versus steroid therapy in pediatric liver allograft recipients under tacrolimus immunosuppression. Am J Transplant 2006; 6:1913.
23. Klintmalm G, Washburn W, Rudich S, et al. Corticosteroid-free immunosuppression with daclizumab in HCV+ liver transplantation recipients: 1-year interim results of the HCV-3 study. Liver Transplant 2007; 13: 1521.
24. Fagiuoli S, Mirante VG, Pompili M, et al.; and the Monotematica AISF 2000-OLT Study Group. Liver transplantation: The Italian experience. Dig Liver Dis 2002; 34: 640.
25. Boillot O, BaulieuxJ, Wolf P, et al. Low rejection rates with tacrolimus based dual and triple regimens following liver transplantation. Clin Transplant 2001; 15: 159.